Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

TSXV:CLAS.H - Post Discussion

Claritas Pharmaceuticals Inc > Perfect NEWS !
View:
Post by Mick00333 on Jul 26, 2021 9:06am

Perfect NEWS !

The study at Royal Brompton & Harefield NHS Foundation Trust was the largest of its kind worldwide.

In this study, 35 Patients with COVID-19 pneumonia who were on ventilation were given inhaled nitric oxide as part of routine care when they were failing to respond to best standard treatments.

This led to significant improvements in oxygen levels and improvements in ventilatory efficiency at 24 hours and for up to five days.
Comment by Moemoney42 on Jul 26, 2021 9:53am
This compound is a game changer in the treatment and management of covid-19.. far better than vaccines IMHO.. no matter what the variant is this treatment with R-107 will stop the virus in its tracks.. nice..!! ;-)
Comment by Kaiser on Jul 27, 2021 4:17pm
LOL! Moe pumping this dumpster fire?! Bahahhahha This guys track record is laughable at best.  This is the same clown who pumped Sona and you know where that is. Like I said this was a gift to shorts post rs! Back down to reality.  Poor no more money moe.
Comment by whisky11 on Jul 27, 2021 4:28pm
Kaiser] LOL! Moe pumping this dumpster fire?! Bahahhahha This guys track record is laughable at best.  This is the same clown who pumped Sona and you know where that is. Like I said this was a gift to shorts post rs! Back down to reality.  Poor no more money moe. whisky11: so what's wrong with R-107 No information? Do you  see short activity today or yesterday? You ...more  
Comment by Kaiser on Jul 27, 2021 6:44pm
This post has been removed in accordance with Community Policy
Comment by Moemoney42 on Jul 27, 2021 8:19pm
Yes Whisky11.. you pretty much have him pegged.. he only cares about hoping someone might loose money on an investment in a short few days span, and doesn't have the foresight to think that Claritas may have a good treatment for any respiratory virus and save lives.. pretty much a BB troll that follows me around beaking off.. not happy with his investment, so to make himself feel worthy, he ...more  
Comment by Kaiser on Jul 27, 2021 11:36pm
Only thing pegged here is you.  I hope everyone makes money but liars like you deserve to lose it all.  Should I quote you again on this stock in particular when you said "at least 30% up from here" that was pre split at .075! anyone taking advice from no knowledge pumpers like you lose every time. What about your failed pump at Sona or Cpg? Should I list a few more?   ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities